Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

Two months af­ter an­nounc­ing Clay Sie­gall’s ar­rival in the C-suite, Mor­phim­mune has nabbed more funds to take its tar­get­ed can­cer ther­a­py bet to­ward the clin­ic.

The fledg­ling biotech filed a $15 mil­lion eq­ui­ty round, from 11 in­vestors, with the SEC this week. Mor­phim­mune did not re­spond to End­points News as of pub­li­ca­tion time. The fi­nanc­ing comes through as Sie­gall set­tles in­to his first post-Seagen role as CEO, pres­i­dent and board mem­ber of Mor­phim­mune.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER